1021 related articles for article (PubMed ID: 12890841)
1. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
Yang JC; Haworth L; Sherry RM; Hwu P; Schwartzentruber DJ; Topalian SL; Steinberg SM; Chen HX; Rosenberg SA
N Engl J Med; 2003 Jul; 349(5):427-34. PubMed ID: 12890841
[TBL] [Abstract][Full Text] [Related]
2. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
George DJ; Kaelin WG
N Engl J Med; 2003 Jul; 349(5):419-21. PubMed ID: 12890838
[No Abstract] [Full Text] [Related]
3. Bevacizumab for patients with metastatic renal cancer: an update.
Yang JC
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6367S-70S. PubMed ID: 15448032
[TBL] [Abstract][Full Text] [Related]
4. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
Rini BI; Halabi S; Taylor J; Small EJ; Schilsky RL;
Clin Cancer Res; 2004 Apr; 10(8):2584-6. PubMed ID: 15102658
[TBL] [Abstract][Full Text] [Related]
5. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
6. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
8. Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
Brieger J; Weidt EJ; Schirmacher P; Störkel S; Huber C; Decker HJ
J Mol Med (Berl); 1999 Jun; 77(6):505-10. PubMed ID: 10475065
[TBL] [Abstract][Full Text] [Related]
9. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
Rini BI; Small EJ
J Clin Oncol; 2005 Feb; 23(5):1028-43. PubMed ID: 15534359
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
11. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeting of VHL gene pathway in clear cell kidney cancer.
Linehan WM
J Urol; 2003 Aug; 170(2 Pt 1):593-4. PubMed ID: 12853837
[No Abstract] [Full Text] [Related]
13. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Ou SS; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2008 Nov; 26(33):5422-8. PubMed ID: 18936475
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
Igarashi H; Esumi M; Ishida H; Okada K
Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma.
Bukowski RM
Nat Rev Clin Oncol; 2009 May; 6(5):253-4. PubMed ID: 19390549
[TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
[TBL] [Abstract][Full Text] [Related]
19. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
[TBL] [Abstract][Full Text] [Related]
20. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
